Sees total revenue increasing by high-single digit percentage. See core tax rate between 18%-22%
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca reports Q2 core EPS $2.17, up 12% at CER
- AZN Earnings: Drugs Giant AstraZeneca (AZN) Zooms Higher on Cancer-Fighting Demand
- Trump administration mulls charging patent holders 1%-5% fee, WSJ reports
- AstraZeneca’s Phase 4 Study on Trastuzumab Deruxtecan: Safety Insights for Indian Patients
- AstraZeneca’s Innovative Study on Bladder Cancer: A Potential Game-Changer